RECHALLENGE

作品数：8被引量：5H指数：1
导出分析报告
相关领域：医药卫生更多>>
相关作者：王鹏张东陈雪琴杨邵瑜李鑫更多>>
相关机构：中国人民解放军总医院杭州市第一人民医院更多>>
相关期刊：《World Journal of Clinical Cases》《World Journal of Clinical Oncology》《中华保健医学杂志》《Chinese Medical Journal》更多>>
-
在结果中检索

检索结果分析

结果分析中...
共 条 记 录，以下是1-8
全选清除导出
参考文献引证文献引用追踪
视图：
排序：
Successful cetuximab rechallenge in metastatic colorectal cancer:A case report
《World Journal of Clinical Oncology》2024年第9期1232-1238,共7页Alexandra Guedes Sandra Silva Sandra Custódio Andreia Capela 
BACKGROUND Metastatic colorectal cancer(mCRC)treatment has been evolving and increasingly driven by tumor biology and gene expression analysis.Rechallenge with epidermal growth factor receptor(EGFR)inhibitors(anti-EGF...
关键词：Metastatic colorectal cancer RAS mutation RAS wild type Anti-epidermal growth factor receptor CETUXIMAB RECHALLENGE Case report 
关注免疫检查点抑制剂发生irAE后免疫治疗再挑战被引量：1
《中华保健医学杂志》2024年第2期129-132,共4页张东 王鹏 
免疫检查点抑制剂(immune-checkpoint inhibitors,ICIs)是近年来肿瘤学领域最重要的突破之一,为不同类型的实体瘤治疗提供了新的范式。ICIs通过阻断免疫内在下调因子,如细胞毒性T淋巴细胞抗原4(CTLA-4)和程序性细胞死亡1(PD-1)或其配体...
关键词：免疫检查点抑制剂(immune-checkpoint inhibitors ICIs) 免疫相关不良事件(immune-related adverse events irAE) 免疫治疗再挑战(immune-checkpoint inhibitors rechallenge) 
Immunotherapy combined with antiangiogenic agents in patients with advanced malignant pleural mesothelioma: A case report
《World Journal of Clinical Cases》2022年第23期8284-8290,共7页Tian-Tian Xuan Guang-Yi Li Si-Bo Meng Zhan-Mei Wang Lin-Li Qu 
BACKGROUND Malignant pleural mesothelioma has limited therapeutic options and a poor outcome. Antiangiogenic agents might increase the efficacy of immunotherapy as second-line treatment of advanced-stage malignancies....
关键词：Pleural mesothelioma Immune checkpoint inhibitor Next-generation Sequencing Immunerelated pneumonia Immunotherapy rechallenge Case report 
Rechallenge pemetrexed-based chemotherapy provides an option for initially benefited patients with advanced lung adenocarcinoma
《Chinese Medical Journal》2021年第17期2119-2121,共3页Jia-Ni Wang Quan-Hui Qiao Xing-Sheng Hu Yu-Tao Liu Zhi-Jie Wang Jian-Chun Duan Yu Feng Hao-Hua Zhu 
To the Editor:Pemetrexed plus platinum(cisplatin or carboplatin)chemotherapy doublets are widely recommended as the standard first-line treatment for non-small cell lung cancer(NSCLC)with no identified genetic mutatio...
关键词：CHEMOTHERAPY PEMETREXED ADENOCARCINOMA 
Fluoropyrimidine-induced cardiotoxicity被引量：3
《World Journal of Clinical Oncology》2020年第12期1008-1017,共10页Andrada Larisa Deac Claudia Cristina Burz Ioana Corina Bocsan Anca Dana Buzoianu 
Cardio-oncology is a discipline based on early screening,monitoring,and treating chemotherapy-induced cardiotoxicity.There are many chemotherapeutics known for their cardiac toxic effects,including fluoropyrimidines.F...
关键词：FLUOROPYRIMIDINES Cancer treatments CARDIOTOXICITY RECHALLENGE PREVENTION ANTIDOTE 
Chemotherapy rechallenge in metastatic colon cancer:A case report and literature review被引量：1
《World Journal of Clinical Oncology》2020年第11期959-967,共9页Tejaswini Parlapalle Reddy Usman Khan Ethan Alexander Burns Maen Abdelrahim 
BACKGROUND Colorectal cancer(CRC)is the third leading cause of cancer-related death in males and females in the United States.Approximately,20%-22%of patients have metastatic disease at the time of presentation,and 50...
关键词：Metastatic colorectal cancer Rechallenge therapy Treatment holiday OXALIPLATIN IRINOTECAN Case report CHEMORESISTANCE Palliative option 
Is there still a place for docetaxel rechallenge in prostate cancer?
《World Journal of Clinical Oncology》2015年第5期99-103,共5页Roberto Petrioli Edoardo Francini Giandomenico Roviello 
Three-weekly docetaxel plus prednisone is the standard first-line cytotoxic treatment for patients with metastatic castrate-resistant prostate cancer(m CRPC). Today, several new treatment options are available for pat...
关键词：ABIRATERONE ACETATE DOCETAXEL Prostate cancer Prostate-specific ANTIGEN RECHALLENGE 
系列问答104——如何理解ADR因果关系评价中的rechallenge和dechallenge?
《药物不良反应杂志》2006年第4期311-311,共1页本刊编辑部 
关键词：因果关系评价 ADR REVIEW 不良反应 DRUG 评价标准 激发 暴露 用药 
全选清除导出
共1页<1>
检索报告 对象比较 聚类工具 使用帮助 返回顶部